Quest Descends On Release Of Test Launch
Date
2/13/2024 10:11:15 AM
(MENAFN- Baystreet)
NCR Loses on Amex Connection
Chrysler Parent Takes Wraps off Halcyon
Biogen Staggers on Q4 Figures
Coca-Cola Posts Mixed
earnings Due To Lower Sales Volumes
Arm Holdings' Stock Rises 99% In Past Five Days Previous Articles Subscribe to Get Small Cap News & Alerts
Glenn Wilkin - Tuesday, February 13, 2024
Quest Descends on Release of Test Launch
Quest Diagnostics (NYSE: DGX) watched its shares move earthward Tuesday, as the leading U.S. provider of diagnostic information services, today announced the launch of MelaNodal PredictTM, a highly advanced predictive gene expression test to help personalize treatment decisions for patients with melanoma, the deadliest form of skin cancer and one of the most common cancers in the United States. Dermatologists and other providers nationwide may begin ordering the test today from Quest Diagnostics, as well as through Dermpath Diagnostics, Quest's subspecialty pathology business.
MelaNodal Predict, according to this morning's news release,“is a lab-developed test validated by Quest Diagnostics and based on technology developed by SkylineDx, an oncology biotechnology company, alongside Mayo Clinic. The technology utilizes a combination analysis of patient age and tumor thickness with advanced gene expression profiling technology. MelaNodal Predict examines a patient's original diagnostic tumor biopsy and applies an algorithm to help providers identify patients with a low or high risk of nodal metastasis (melanoma that has spread to the lymph nodes).”
Said company official Kristie Dolan, "By leveraging our scale, we can provide MelaNodal Predict to patients and treating physicians across the country to support clinical decision making. The MelaNodal Predict test's results will help physicians identify their patient's risk of metastasis to assist in individualizing surgical decisions and patient management plans."
DGX shares lost 45 cents to $129.56.
About Us Contact Us Advertise License Our Content Jobs Disclaimer Privacy Policy
Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks
MENAFN13022024000212011056ID1107846793
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.